Investigational drug · Phase 2
Ibezapolstat
Also called: ACX-362E
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Clostridium Difficile Infection Recurrence.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "Ibezapolstat"
First trial start
2026
Sep 25, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Ibezapolstat", any sponsor or status.
Conditions studied
As listed on its trial records.
- Clostridium Difficile Infection Recurrence
Approved drugs for the same conditions: C. difficile infection · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "Ibezapolstat" as an intervention, largest first.
Acurx Pharmaceuticals Inc.Industry
NCT04247542 · 53 participants · Start Mar 6, 2020 · Primary completion Oct 3, 2023
Drug: Ibezapolstat; Vancomycin · For: Clostridium Difficile Infection
Sites: Scottsdale, Arizona; Apple Valley, California; Camarillo, California · 29 sites in all
- ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile InfectionRecruiting
Acurx Pharmaceuticals Inc.Industry
NCT07513285 · 20 participants (planned) · Start Sep 25, 2026 · Primary completion Sep 29, 2027
Drug: Ibezapolstat · For: Clostridium Difficile Infection Recurrence
Sites: Sacramento, California; Hamden, Connecticut; Coral Gables, Florida · 19 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- The effects of novel oral preclinical PolC inhibitor antibiotic candidates on the gut microbiome in a murine thigh infection model.
Shremo Msdi A, Begum K, Hu C, et al. · Microbiol Spectr 2026
- Novel options for the management of C. difficile: a look into the future.
Granata G, Petrosillo N, Taglietti F · Expert Rev Anti Infect Ther 2026
- Some Newer Antibiotics Active Against Helicobacter pylori and Anaerobic Bacteria and the Potential Benefits of Their Wider Availability in More Countries: A Narrative Review.
Boyanova L, Boyanova LY, Medeiros J, et al. · Antibiotics (Basel) 2026
- Newer Therapeutics to Selectively Kill Clostridioides difficile and Restore the Microbiome.
Granata G, Petrosillo N · Infect Dis Rep 2026
- What potential do DNA polymerase IIIC (PolC) inhibitors hold for the treatment of Clostridioides difficile infection?
Khanna S · Expert Opin Pharmacother 2026
- Microbiome-selective DNA Pol IIIC inhibitors in oncology infection management.
Mehmood MS, Abid M, Danaf N · Ann Med Surg (Lond) 2026
Also in development for Clostridium Difficile Infection Recurrence
- VE303Phase 31 trial
Vedanta Biosciences, Inc. · Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.